Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

A Swiss pharmaceutical giant is developing a next-generation allergy treatment that may work faster and more effectively than current therapies. The news is potentially positive for the company's growth and market share in the allergy category, but impact is contingent on forthcoming clinical data and regulatory approvals, so near-term effects are speculative.

Analysis

A Swiss pharmaceutical giant is developing a next-generation allergy treatment that may work faster and more effectively than current therapies. The news is potentially positive for the company's growth and market share in the allergy category, but impact is contingent on forthcoming clinical data and regulatory approvals, so near-term effects are speculative.